Clofazimine: A Promising Inhibitor of Rabies Virus.
approved drugs
clofazimine
high-throughput screening
in vivo
rabies virus
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
08
2020
accepted:
09
02
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
With an almost 100% mortality rate, rabies virus (RABV) infection is a global concern. Limited post-exposure prophylaxis and lack of an effective treatment necessitate novel antiviral therapies against RABV. Here, using a high-throughput screening (HTS) method developed in our lab, 11 candidates with anti-RABV activity were identified from a library of 767 clinical drugs. Clofazimine (CFZ), an anti-leprosy drug, displayed an EC
Identifiants
pubmed: 33815101
doi: 10.3389/fphar.2021.598241
pii: 598241
pmc: PMC8012719
doi:
Types de publication
Journal Article
Langues
eng
Pagination
598241Informations de copyright
Copyright © 2021 Wu, Cao, Lei, Liu, Li, Yu, Xie, Li, Zhao, Chen, Huang, Xiao, Yu, Song, Li and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Molecules. 2012 Apr 17;17(4):4545-59
pubmed: 22510605
Eur J Clin Pharmacol. 2001 Nov;57(9):621-9
pubmed: 11791890
J Invest Dermatol. 2018 Mar;138(3):697-703
pubmed: 29042210
Antiviral Res. 2018 Jun;154:1-9
pubmed: 29601893
Curr Protoc Pharmacol. 2010 Dec;Chapter 13:Unit 13B.3
pubmed: 21935898
Sci Rep. 2017 Feb 20;7:42769
pubmed: 28218278
MMWR Morb Mortal Wkly Rep. 2012 Feb 3;61(4):61-5
pubmed: 22298301
J Infect Dis. 2016 Apr 15;213(8):1253-61
pubmed: 26655300
J Med Virol. 2019 Nov;91(11):2016-2024
pubmed: 31294846
Elife. 2014 Oct 21;3:e03679
pubmed: 25333492
Bull World Health Organ. 1973 May;48(5):535-41
pubmed: 4544144
Antiviral Res. 2019 Dec;172:104641
pubmed: 31672666
J Virol. 2017 Oct 13;91(21):
pubmed: 28814523
Antimicrob Agents Chemother. 1992 Aug;36(8):1750-5
pubmed: 1416859
Curr Pharm Des. 2014;20(2):189-200
pubmed: 23701546
Annu Rev Virol. 2015 Nov;2(1):451-71
pubmed: 26958924
Br J Pharmacol. 2015 Nov;172(21):5161-73
pubmed: 26276903
Int J Lepr Other Mycobact Dis. 1981 Jun;49(2):167-76
pubmed: 7196886
Nat Rev Dis Primers. 2017 Nov 30;3:17091
pubmed: 29188797
J Infect Dis. 2016 Aug 1;214(3):502-3
pubmed: 27190188
Antiviral Res. 2013 Jul;99(1):61-7
pubmed: 23369672
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2627-38
pubmed: 26856848
Antimicrob Agents Chemother. 2011 Nov;55(11):5185-93
pubmed: 21844321
N Engl J Med. 2005 Jun 16;352(24):2508-14
pubmed: 15958806
J Antimicrob Chemother. 2012 Feb;67(2):290-8
pubmed: 22020137
Mini Rev Med Chem. 2002 Apr;2(2):145-61
pubmed: 12370076
Vaccine. 2019 Aug 2;37(33):4724-4735
pubmed: 29805091
World Health Organ Tech Rep Ser. 2013;(982):1-139, back cover
pubmed: 24069724
Vaccine. 2019 Aug 2;37(33):4686-4693
pubmed: 29132993
Lancet. 2014 Oct 11;384(9951):1389-99
pubmed: 24828901
Bioinformation. 2015 Nov 30;11(11):506-8
pubmed: 26912951
J Virol. 2006 Oct;80(20):10270-3
pubmed: 17005706